Welcure Drugs & Pharmaceuticals Ltd.

BSE: 524661 SECTOR: Trading  3484   24   1

8.42
-0.44 (-4.97%)
BSE: Today, 05:10 PM

Price Summary

Today's High

₹ 8.42

Today's Low

₹ 8.42

52 Week High

₹ 12.08

52 Week Low

₹ 0

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

11.38 Cr.

Enterprise Value

11.33 Cr.

No. of Shares

1.35 Cr.

P/E

0

P/B

7.98

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  1.05

CASH

0.05 Cr.

DEBT

0 Cr.

Promoter Holding

14.12 %

EPS (TTM)

₹  0

Sales Growth

61.58%

ROE

131.66 %

ROCE

131.9%

Profit Growth

686.17 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year61.58%
3 Year38.66%
5 Year5.95%

Profit Growth

1 Year686.17%
3 Year69.16%
5 Year-8.4%

ROE%

1 Year131.66%
3 Year33.34%
5 Year28.57%

ROCE %

1 Year131.9%
3 Year33.73%
5 Year28.93%

Debt/Equity

0

Price to Cash Flow

269.6

Interest Cover Ratio

552

CFO/PAT (5 Yr. Avg.)

0.729081416189726

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2021 14.12 0
Jun 2021 14.12 0
Mar 2021 14.12 0
Dec 2020 14.12 0
Sep 2020 14.12 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 38.6602446604955% for the Past 3 years.
  • Company has been maintaining healthy ROE of 33.3413475055817% over the past 3 years.
  • Company has been maintaining healthy ROCE of 33.7274129193807% over the past 3 years.
  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 0 days.
  • Company has a healthy liquidity position with current ratio of 20.2777777777778.

 Limitations

  • Company has contingent liabilities of 0.3299 Cr.
  • The company is trading at a high PE of 0.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
Net Sales 0.03 0 0.05 0.02 0
Total Expenditure 0.02 0 0.01 0.05 0.01
Operating Profit 0.01 0 0.04 -0.02 -0.01
Other Income 0 0 0 0 0
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.01 0 0.04 -0.02 -0.01
Tax 0 0 0 0 0
Profit After Tax 0.01 0 0.04 -0.02 -0.01
Adjusted EPS (Rs) 0.01 0 0.03 -0.02 -0.01

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 0.09 0.05 0.08 0.08 0.13
Total Expenditure 0.06 0.07 0.08 0.09 0.08
Operating Profit 0.03 -0.02 0 -0.01 0.06
Other Income 0 0 0 0 0
Interest 0 0 0 0 0
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.03 -0.02 0 -0.01 0.06
Tax 0 0 0 0 0
Net Profit 0.03 -0.02 0 -0.01 0.06
Adjusted EPS (Rs.) 0.02 -0.02 0 -0.01 0.05

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 12.12 12.12 12.12 12.12 12.12
Total Reserves -12.08 -12.1 -12.09 -12.1 -12.05
Borrowings 0 0 0 0 0
Other N/C liabilities 0 0 0 0 0
Current liabilities 0 0 0.01 0.01 0
Total Liabilities 0.04 0.02 0.03 0.02 0.07
Assets
Net Block 0 0 0 0 0
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0 0 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 0.04 0.02 0.03 0.02 0.07
Total Assets 0.04 0.02 0.03 0.02 0.07
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 0.03 -0.02 0 -0.01 0.06
Adjustment 0 0 0 0 0
Changes in Assets & Liabilities -0.01 0.01 0 0 -0.01
Tax Paid 0 0 0 0 0
Operating Cash Flow 0.02 -0.01 0 -0.01 0.04
Investing Cash Flow 0 0 0 0 0
Financing Cash Flow 0 0 0 0 0
Net Cash Flow 0.02 -0.01 0 -0.01 0.04

Corporate Actions

Investors Details

PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Promoters 14.12 14.12 14.12 14.12 14.12
dharam chand jain 14.12 14.12 14.12 14.12 14.12
PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Investors 85.88 85.88 85.88 85.88 85.88
sandeep jain 15.07 15.07 15.07 15.07 15.07
lata jain 7.85 7.85 7.85 7.85 7.85
sanjeev jain 7.11 7.11 7.11 7.11 7.11
bits limited 3.67 3.67 3.67 3.67 -
bits ltd - - - - 2.31
welcure pharmaceut... - - - - -
welcure pharmaceut... 2.87 - - - -
welcure pharmaceut... - - - 2.87 2.87
welcure pharmaceut... - 2.87 - - -
welcure pharmaceut... - - 2.87 - -
vizwise commerce p... 2.24 2.24 - 2.24 2.24
vizwise commercial... - - 2.24 - -
dinesh kumar jain - - - - 1.10

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Welcure Drugs&Pharma Stock Price Analysis and Quick Research Report. Is Welcure Drugs&Pharma an attractive stock to invest in?

 

Stock investing requires careful analysis of financial data to find out the company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement. This can be time-consuming and cumbersome. An easier way to find out about a company's performance is to look at its financial ratios, which can help to make sense of the overwhelming amount of information that can be found in a company's financial statements.

Here are the few indispensable tools that should be a part of every investor’s research process.

  • PE ratio: - Price to Earnings' ratio, which indicates for every rupee of earnings how much an investor is willing to pay for a share. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Welcure Drugs&Pharma has a PE ratio of -12028.5714285714 which is low and comparatively undervalued .

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Welcure Drugs&Pharma has ROA of 112.909836065574 % which is a good sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Welcure Drugs&Pharma has a Current ratio of 20.2777777777778 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Welcure Drugs&Pharma has a ROE of 131.660692951024 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Welcure Drugs&Pharma has a D/E ratio of 0 which means that the company has low proportion of debt in its capital.

  • Inventory turnover ratio: - Inventory Turnover ratio is an activity ratio and is a tool to evaluate the liquidity of a company's inventory. It measures how many times a company has sold and replaced its inventory during a certain period of time. Welcure Drugs&Pharma has an Inventory turnover ratio of 0 which shows that the management is inefficient in relation to its Inventory and working capital management.

  • Sales growth: - Welcure Drugs&Pharma has reported revenue growth of 61.5757575757576 % which is fair in relation to its growth and performance.

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Welcure Drugs&Pharma for the current financial year is 41.2603150787697 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Welcure Drugs&Pharma is Rs 0 and the yield is 0 %.

Brief about Welcure Drugs&Pharma

X